Back to Journals » Drug Design, Development and Therapy » Volume 8

Daclatasvir: potential role in hepatitis C [Corrigendum]

Authors Lee C

Received 6 March 2014

Accepted for publication 6 March 2014

Published 20 March 2014 Volume 2014:8 Pages 325—326

DOI https://doi.org/10.2147/DDDT.S63655


Lee C. Drug Des Devel Ther. 2013;7:1223–1233.
On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor, DCV, describing its discovery, mechanism of action, resistance profile, in vitro and in vivo efficacy and toxicity, and polymorphism."


Read the original article


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]